<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556215</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-ENT-BET</org_study_id>
    <secondary_id>MH CZ - DRO - FNOs/2016</secondary_id>
    <nct_id>NCT03556215</nct_id>
  </id_info>
  <brief_title>Balloon Eustachian Tuboplasty in Treatment of Chronic Eustachian Tube Dysfunction</brief_title>
  <official_title>Balloon Eustachian Tuboplasty in Treatment of Chronic Eustachian Tube Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of Eustachian tube (ET) dysfunction in adults reaches 1%. It causes a feeling
      of fullness in the ear, otalgia and hearing loss and can lead to recurrent acute otitis
      media, development of chronic otitis media with effusion and cholesteatoma. Endoscopic
      transnasal balloon ET dilatation is a novel surgical technique for ET dysfunction. The main
      goal is to restore ET function by dilation its cartilaginous part leading to better
      ventilation and drainage of the middle ear. However, its real effect in the treatment of
      particular subgroups of patients with ET dysfunction remains unknown. Patients are mostly
      evaluated as one group.

      Adults with chronic ET dysfunction will be strictly divided into particular subgroups and
      included in the study. Subgroups will be compared in order to identify treatment effect in
      particular subgroups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of Eustachian tube (ET) dysfunction in adults reaches 1%. It causes a feeling
      of fullness in the ear, otalgia and hearing loss and can lead to recurrent acute otitis
      media, development of chronic otitis media with effusion and cholesteatoma. Endoscopic
      transnasal balloon ET dilatation is a novel surgical technique for ET dysfunction. The main
      goal is to restore ET function by dilation its cartilaginous part leading to better
      ventilation and drainage of the middle ear. However, its real effect in the treatment of
      particular subgroups of patients with ET dysfunction remains unknown. Patients are mostly
      evaluated as one group.

      Adults with chronic ET dysfunction will be strictly divided into particular subgroups and
      included in the study. The otomicro(endo)scopy, symptoms severity according to VAS (Visual
      Analogue Pain Scale), ETDQ-7 (Eustachian Tube Dysfunction Questionnaire) questionnaire,
      tympanometry, audiometry and the possibility of Valsalva and Toynbee maneuver will be used to
      evaluate the effect of balloon ET dilatation. Only patients with standard treatment failure
      will be included in the study. Tuboplasty with and without myringotomy will be performed (and
      compared) in patients with chronic otitis media with effusion. Subgroups will be compared in
      order to find patients who could profit from the treatments the most.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional parallel randomized controlled prospective trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking was used in the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Otomicro(endo)scopy</measure>
    <time_frame>36 months</time_frame>
    <description>Otomicro(endo)scopy will be used to assess the presence or absence of effusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms severity according to Visual Analogue Scale</measure>
    <time_frame>36 months</time_frame>
    <description>Symptoms severity will be assessed on Visual Analogue Scale (on the scale of 1-10). Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETDQ-7 questionnaire</measure>
    <time_frame>36 months</time_frame>
    <description>The patients will be asked to fill-in the Eustachian Tube Dysfunction Questionnaire in order to assess the symptoms of Eustachian Tube Dysfunction (ETD). The ETDQ-7 is a valid and reliable symptom score for use in adult patients with ETD. The ETDQ-7 tool consists of seven items with a scale of graduated responses ranging from 1 to 7, with &quot;1&quot; corresponding to the absence of the suggested symptom and &quot;7&quot;, to maximum symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tympanometry</measure>
    <time_frame>36 months</time_frame>
    <description>Type of tympanometry curve (A, B, C) according to Joerger et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Audiometry</measure>
    <time_frame>36 months</time_frame>
    <description>Hearing loss according to WHO classification (mild, moderate, severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tubomanometry</measure>
    <time_frame>36 months</time_frame>
    <description>Assessment of opening pressure in Eustachian tube in mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possibility of Valsalva and Toynbee manoeuvre</measure>
    <time_frame>36 months</time_frame>
    <description>The possibility or inability of Valsalva and Toynbee manoeuvre (yes/no)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Chronic Eustachian Tube Dysfunction</condition>
  <condition>Chronic Recurrent Otitis Media</condition>
  <condition>Effusion After Tympanostomy</condition>
  <arm_group>
    <arm_group_label>Effusion, Eustachian tube dilatation device and myringotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effusion, Eustachian tube dilatation device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No effusion, Eustachian tube dilatation device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eustachian tube dilatation device</intervention_name>
    <description>Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.</description>
    <arm_group_label>Effusion, Eustachian tube dilatation device</arm_group_label>
    <arm_group_label>Effusion, Eustachian tube dilatation device and myringotomy</arm_group_label>
    <arm_group_label>No effusion, Eustachian tube dilatation device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Myringotomy</intervention_name>
    <description>Myringotomy will be performed using a standard procedure.</description>
    <arm_group_label>Effusion, Eustachian tube dilatation device and myringotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with chronic Eustachian tube dysfunction lasting more than 6 months,
             with or without recurrence of chronic otitis media with effusion after tympanostomy

        Exclusion Criteria:

          -  anatomic obstruction in nasopharynx

          -  nasopharyngeal cancer

          -  head and neck cancer

          -  other middle ear surgery except for myringotomy or tympanostomy

          -  chronic suppurative otitis media

          -  patients who could not undergo general anesthesia

          -  patients who did not give consent to be included in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Komínek, prof.,MD,Ph.D.,MBA</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Formánek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petr Vávra, Ass.Prof.,MD,Ph.D.</last_name>
    <phone>0042059737</phone>
    <phone_ext>2544</phone_ext>
    <email>petr.vavra@fno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <state>Hradec Králové Region</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lukáš Školoudík, MD,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Vávra, Ass.Prof.,MD,Ph.D.</last_name>
      <phone>0042059737</phone>
      <phone_ext>2544</phone_ext>
      <email>petr.vavra@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Formánek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Komínek, prof.,MD,Ph.D.,MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debora Jančatová, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karol Zeleník, MD,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>otitis media with effusion</keyword>
  <keyword>balloon tuboplasty</keyword>
  <keyword>Eustachian tube</keyword>
  <keyword>Eustachian tube dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The investigators have not decided to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

